期刊文献+

胃肠肿瘤综合诊治的进步与外科医生观念的转变 被引量:4

原文传递
导出
摘要 21世纪第一个10年即将过去.世界范围内肿瘤相关研究获得了众多成果.单纯依靠“刀法纯熟”的“外科”医生演绎精美手术或“浴血奋战”就可以治疗肿瘤的崇高形象受到质疑。观念的更新对外科医生、尤其是普通外科医生提出了更高的要求。
作者 刘荫华
出处 《中华胃肠外科杂志》 CAS 北大核心 2010年第1期19-21,共3页 Chinese Journal of Gastrointestinal Surgery
  • 相关文献

参考文献8

  • 1World Health Organization.Preventing chronic diseases:a vital investment.2009.http://www.who.int/chp/chronic_disease_report/presentation/en/index.html.
  • 2NCCN胃癌专家组.胃癌临床实践指南(中国版).2009.http://www.nccn-asia.org/pdf/2009_Gastric_Cancer_Ch_m.pdf.
  • 3NCCN结肠癌专家组.结肠癌临床实践指南(中国版).2009.http://www.nccn-asia.org/pdf/2009_Colon_Cancer_Ch_m.pdf.
  • 4NCCN直肠癌专家组.直肠癌临床实践指南(中国版).2009.http://www.nccn-asia.org/pdf/2009_Rectal_Cancer_Ch_m.pdf.
  • 5张俊,陈功.第11届世界胃肠道肿瘤大会会议亮点报道及点评.2009.http://www.24hmb.com/ESM02009/ESMO-Spi/20091029175233.shtml.
  • 6National Surgical Adjuvant Breast and Bowel Project.NSABP CLINICAL TRIALS OVERVIEW.2009.http://www.nsabp.pitt.edu/NSABP_Protocols.asp.
  • 7Eisenhauer EA,Therasse P.New response evaluation criteriain solid tumours:revised RECIST guideline(version 1.1).Eur J Cancer,2009,45(2):228-247.
  • 8Saini A,Norman AR,Cunningham D,et al.Twelve weeks of protracted venous infusion of fluorouracil (5-Fu) and folinic acid as adjuvant treatment in colorectal cancer.Br J Cancer,2003,88(12):1859-1865.

同被引文献52

  • 1杨小冬,刘福坤,许哲,陈彻,李刚,吴晓宇,张新华,孙桂勤,李宁,黎介寿.生长抑素受体在结直肠癌和正常黏膜表达及与细胞增殖和凋亡的关系[J].肠外与肠内营养,2005,12(1):29-32. 被引量:7
  • 2Cheng-Zhi Qiu,Chuan Wang,Zhong-Xin Huang,Shi-Ze Zhu,You-Yi Wu,Jian-Long Qiu.Relationship between somatostatin receptor subtype expression and clinicopathology,Ki-67,Bcl-2 and p53 in colorectal cancer[J].World Journal of Gastroenterology,2006,12(13):2011-2015. 被引量:13
  • 3NCCN直肠癌临床实践指南(中国版)专家组.直肠癌临床实践指南(中国版-2009).[2009-12—14].http://www.nccn—asia.org/pdf/2009_Rectal_Cancer_Ch_m.pdf.
  • 4The NSABP Foundation, Inc. NSABP Clinical Trials Overview. [ 2009-12-18 ]. http ://www. nsabp. pitt. edu/NSABP_Protocols, asp.
  • 5Tjandra JJ, Kilkenny JW, Buie WD, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum,2005,48 : 411-423.
  • 6Karapetis CS, Khambata FS, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med ,2008,359 : 1757-1765.
  • 7Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol,2008,26:374-379.
  • 8Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med ,2009,360 : 1408-1418.
  • 9中国抗癌协会临床肿瘤学协作专业委员会.基因检测大肠癌,靶向治疗个体化.[2009-4-2].http://news.csco.net.cn/class/detail.asp?u=296.
  • 10Zubrod CG, Schneiderman SM, Frei E, et al. Appraisal of methodsfor the study of chemotherapy of cancer in man: Comparativetherapeutic trial of nitrogen mustard and thiophosphamide. J Chronic Dis, 1960,11:7-33.

引证文献4

二级引证文献112

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部